Charles Erlichman
Mayo Clinic
6
6
4
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+6 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (6)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Stanislaw R. Burzynski, MD, PhD
Burzynski Research Institute
Shared therapeutic areas:
Thomas E. Witzig, MD
Mayo Clinic
Shared therapeutic areas:
Worked with same sponsors:
Mary Horowitz, MD
Center for International Blood and Marrow Transplant Research
Shared therapeutic areas:
Worked with same sponsors:
Ingrid Mayer, MD
Vanderbilt-Ingram Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Heinz-Josef Lenz, MD
University of Southern California
Shared therapeutic areas:
Worked with same sponsors:
Scot C. Remick, MD
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Corey J. Langer, MD
Fox Chase Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Gustavo Leone
Medical University of South Carolina, Hollings Cancer Center
Shared therapeutic areas:
Jorge Cortes, MD
M.D. Anderson Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
William I. Bensinger, MD
Fred Hutchinson Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Publications (0)
No publications found for this investigator.
Clinical Trials (6)
Showing 6 of 6 trials
GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery
Dasatinib and Lapatinib Ditolsylate in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery
2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors
Tanespimycin, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors
Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
CCI-779 and EKB-569 in Treating Patients With Advanced Solid Tumors
All 6 trials loaded